Semaglutide is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin signaling
Heres where semaglutide shines: A 2025 meta-analysis (a birds eye examination of existing literature on a given topic) concluded GLP-1s could significantly reduce the prevalence of sleep apnea due to their research showing a threefold decrease in AHI, the medical metric used to measure how disruptive sleep apnea is on rest
Improves insulin sensitivity and cardiovascular markers
The quality control standards at synthesis facilities vary enormously, and the distance between you and the manufacturer makes resolving disputes difficult
Ive really only mentioned the biggest con of GLP-1 agonists which is a potential risk of thyroid cancer but there are others to consider such as muscle loss as well
Rob Berberian builds individualized treatment plans for patients throughout Newport Beach, Orange County, Los Angeles, and California combining the following approaches